IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma

IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma

Purpose: Vascular endothelial growth factor tyrosine kinase inhibitors (TKIs) have been the standard of care for advanced and metastatic clear cell renal cell carcinoma (ccRCC). However, the therapeutic effect of TKI monotherapy remains unsatisfactory given the high rates of acquired resistance to T...

Full description

Bibliographic Details
Main Authors: Se Un Jeong, Ja-Min Park, Sun Young Yoon, Hee Sang Hwang, Heounjeong Go, Dong-Myung Shin, Hyein Ju, Chang Ohk Sung, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho
Format: Article
Language:English
Published: Korean Urological Association 2024-01-01
Series:Investigative and Clinical Urology
Subjects:
carcinoma renal cell
drug resistance
ifitm3 protein human
mitogen-activated protein kinase 1
tnf receptor-associated factor 6
Online Access:https://www.icurology.org/pdf/10.4111/icu.20230294

Internet

https://www.icurology.org/pdf/10.4111/icu.20230294

Similar Items